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BLURRED LINES: EVOLVING ROLE OF 
RADIATION IN STAGE IV CANCER
3RD ANNUAL PRIMARY CARE AND ONCOLOGY SYMPOSIUM
MAY 31, 2019
DR. ROBERT ASH, DEPARTMENT RADIATION ONCOLOGY, ST JOSEPH HOSPITAL, 
ORANGE
OBJECTIVES:
-REVIEW TRADITIONAL SETTINGS OF RADIATION
-ROLE OF LOCALLY ABLATIVE RADIATION IN OLIGOMETASTATIC DISEASE
-ABSCOPAL EFFECT AND ROLE OF RADIATION WITH IMMUNOTHERAPY IN     
STAGE IV DISEASE
-TECHNOLOGIES USED TO TREAT OLIGOMETASTATIC DISEASE
CONVENTIONAL SETTINGS FOR 
RADIOTHERAPY
 PRIMARY/RADICAL RADIOTHERAPY ( OFTEN COMBINED WITH 
SYSTEMIC THERAPY)
 PREOPERATIVE /NEOADJUVANT                 SURGERY
 SURGERY                  POSTOPERATIVE/ADJUVANT
 PALLIATIVE














First described in 1995 by Hellman and Weichselbaum
From the Greek “oligos” : scant, few
What is it? 1? 3? 5? Metastatic lesion?
Is it curative? ( surgery has shown it may be)
Other ablative therapies
How to integrate with systemic therapy?

ROLE OF RADIATION IN STAGE IV 
DISEASE
 PALLIATIVE
 LOCALLY ABLATIVE IN OLIGOMET DZ ( PRIMARY AND METS)
 ABSCOPAL EFFECT WITH IMMUNOTHERAPY ( EVEN IN WIDELY MET 
STAGE IV)
RATIONALE
 OLIGO METS BETTER OS THAN WIDELY MET DZ
 SURGICAL ABLATION FOR OLIGOMETS IN STAGE IV 
 SBRT FOR  PRIMARY LUNG CAN GIVE EXCELLENT LOCAL CONTROL  
( 60% PATH CR , 80%  RADIOGRAPHIC LC )
 ? SBRT FOR ABLATION OF OLIGOMETS LESS INVASIVE THAN 
SURGERY

GOMEZ ET AL,  LANCET , VOL17, 2016
 RANDOMIZED PH 2, MULTICENTER
 STAGE IV NSCLC, 3 OR FEWER METS
 CISPLAT DOUBLET OR 3 OR MORE MONTHS OF EGFR OR ALK 
INHIBITOR
 RANDOMIZED TO MAINTENANCE OR ABLATIVE RT OR SURGERY
 74 PTS ENROLLED
 MED FLUP 12 MONTHS
 PFS 11.9 VS 3.9 MONTHS
SABR–COMET TRIAL ( PALMA ET AL)
 Randomized ph II trial design :  palliative SOC ( ARM 1) vs SOC plus 
SABR (Arm 2)
 Purpose: To determine if SABR impacts OS, PFS, toxicity, QOL in pt
with oligomets with controlled primary
 Eligibility: controlled primary, 1-5 mets ( amenable to SABR), ECOG 
0-1, life expectancy >6 mo.
 Stratified 1-3 vs 4-5 mets , randomized 1:2
 Results: 99 randomized( 33 arm 1 vs 66 arm 2 ) b/t 2012-16
 Breast, lung ( 20%), colorectal , prostate  ( 93%=1-3 mets)
 Med f/u 27mo, OS 28 mo vs 41 mo, PFS 6 mo vs 12 mos.
 Grade >/= 2 tox : 9 % vs 30 % ( 3 treatment related grade 5  
toxicities arm 2)
 No diff Fact – G or other QOL measures.
STAMPEDE TRIAL: PARKER ET AL, THE 
LANCET, DEC. 2018
 phase III, MET PROSTATE CA
 2061 PTS FROM UK / SWITZERLAND, MED AGE 68
 SECOND RANDOMIZATION : SYSTEMIC THERAPY  +/- PROSTATE RT 
 HIGH ( >4) VS LOW ( </= 3) MET BURDEN
 OS NO DIFF FOR ENTIRE GROUP  (54% VS 53%)
 LOW BURDEN:  3YR OS 81% VS 73%, P=.007
 GRADE 3-4 TOXICITY 5%
CLINICAL TRIALS: LU-002
 Randomized phase II/III
 Stage IV NSCLC, 3 or fewer extracranial sites of mets
 Pts receive 4 cycles of induction chemotherapy with 
stable/partial response
 Maintenance therapy alone vs maintenance therapy + LCT
 Endpoints PFS, OS
ABSCOPAL EFFECT
 “Ab”- position away from ; “scopos”- a target for shooting at
 Hypothesis in the treatment of metastatic cancer whereby 
shrinkage of untreated tumors occur concurrently with tumors 
within the scope of a locally ablative region.
 Immune-mediated response
 Abscopal effect is rare with radiation alone
 MANY case reports (melanoma, lymphoma)
RATIONALE FOR COMBINING RADIATION 
WITH IMMUNOTHERAPY
 Radiation debulks tumor to overcome T cell 
exhaustion
 Radiation upregulates pro-immunogenic tumor cell 
surface markers
 Immunotherapy can block anti-immunogenic 
pathways that radiation induces
 Immunotherapy increases the radiation abscopal 
effect even in non-immunogenic cancer types




CLINICAL DATA ON IMMUNOTHERAPY 
+ RT IN STAGE III AND IV NSCLC
•Med PFS 6.3 mo with extracranial RT vs. 2 mo without RT (6-mo PFS 54% vs. 21%)
•Med OS 11.6 mo with extracranial RT vs. 5.3 mo with RT (6-mo OS 75% vs. 45%)
•More pembro-related lung tox (13% RT vs 1% noRT) but no difference in Grade3+ 
pneumonitis
KEYNOTE-001 – Stage IV patients 
who received previous 
radiotherapy had longer PFS and 
OS with pembrolizumab than 
patients who had no radiotherapy
•Objective Response Rate 41% with SBRT vs. 17% without SBRT
•CR (1 vs 0), PR (12 vs 6), stable (6 vs 7), progressive dz (13 vs 19) for SBRT vs no SBRT
•Any grade Cough or SOB 30-33% vs. 19-22%
•Any grade Pneumonitis 11% vs. 8% 
PEMBRO-RT – SBRT to a metastatic 
site within 7 days of starting 
pembrolizumab improved ORR
•Med PFS 17.2 mo with durvalumab vs 5.6 mo with placebo
•12-mo OS 83% vs 75%, 24-mo OS 66% vs 56%
•Grade 3-4 pneumonitis (drug- or RT-induced) n.s. different with durvalumab 3.4% vs. 
2.6%
•Any grade lung AE 34% vs. 25% 
PACIFIC – After 
chemoradiotherapy, durvalumab
improved PFS and OS for stage III 
patients
TECHNOLOGY
 STEREOTACTIC RADIOSURGERY (1 TREATMENT)
 STEREOTACTIC RADIOTHERAPY ( 1-5 TREATMENTS)
 CHOICE OF FRACTIONS OFTEN DEPENDS ON SITE, NORMAL TISSUE 
COMPLICATIONS




 RAPID ON BOARD IMAGING FOR IGRT
 MORE PRECISE ON BOARD IMAGING (ITERATIVE CONE BEAM CT)
 6 DEGREE FREEDOM COUCH
 HIGHER DOSE RATE/ FASTER TREATMENT




Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences
Immunological Reviews, Volume: 280, Issue: 1, Pages: 249-279, First published: 13 October 2017, DOI: (10.1111/imr.12573) 
CONCLUSIONS
 RADIATION  THERAPY MAY IMPROVE PFS/OS IN PTS WITH LIMITED 
STAGE IV CANCER DUE TO ITS LOCALLY ABLATIVE PROPERTIES
 RADIATION MAY IMPROVE PFS/OS IN WIDELY MET CANCER  DUE TO 
ABSCOPAL EFFECT IN COMBINATION WITH IMMUNOTHERAPY
 STILL QUESTIONS ON TIMING/SEQUENCING OF RT WITH 
IMMUNOTHERAPY
 DOSE/FRACTIONATION? BEST LESION TO TREAT? 
